ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2022
HOPE in action: A prospective multicenter pilot study of liver transplantation from donors with HIV to recipients with HIV.
Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 71 citations in OpenAlex.
- HIV-Positive Liver Transplant Does not Alter the Latent Viral Reservoir in Recipients With Antiretroviral Therapy-Suppressed HIV.The Journal of infectious diseases · 2023Trial
- HHV-8 Infection in Solid-Organ Transplant-Pathogenesis, Epidemiology, Clinical Manifestations and Management.Reviews in medical virology · 2026Review
- Kaposi Sarcoma-Associated Herpesvirus Risk and Disease in Kidney Donors and Transplant Recipients With HIV in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Machine Perfusion Across Marginal Liver Grafts: Benefits and Challenges.Journal of personalized medicine · 2026Review
- Influence of HIV Status on Organ Procurement and Allocation: A Discrete Choice Experiment of Australian Transplant Providers.Open forum infectious diseases · 2026Article
- Infections After Kidney Transplantation From Donors With HIV to Recipients With HIV.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Observational
- Potential pool of cardiothoracic organs from donors with HIV.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2026Article
- Increased rate of deceased donor liver transplantation for candidates willing to receive organs from donors with human immunodeficiency virus.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026Article
- Kaposi sarcoma in solid organ transplant recipients: updates in epidemiology, diagnosis, treatment and prevention.Frontiers in immunology · 2026Review
- Sexual and Gender Minorities in Organ and Tissue Donation and Transplantation (OTDT): A Survey of Canadian OTDT Health Care Workers.Canadian journal of kidney health and disease · 2026Article
- What barriers impede the access to healthcare toward Lesbian and Gay men: a cross-sectional study of liver transplant surgeons in China.Annals of medicine · 2025Article
- Solid organ transplantation in people with HIV: Outcomes, obstacles and opportunities.HIV medicine · 2025Review
- HIV Superinfection in Kidney Transplant Recipients With HIV Who Received Organs From Donors With HIV.The Journal of infectious diseases · 2025Observational
- Updates on Donor-Derived Infection in Solid Organ Transplantation, Report from the 2024 GTI (Infection and Transplantation Group) Annual Meeting.Transplant international : official journal of the European Society for Organ Transplantation · 2025Article
- Brief Report: Unmet Need for Solid Organ Transplantation Among People With HIV and End-Stage Kidney or Liver Disease: A Brief Report From the HIV Outpatient Study, 2009-2023.Journal of acquired immune deficiency syndromes (1999) · 2024Article
- Increased Infectious Risk Donor Status and Equity-Relevant Predictors of Organ Donation Organization Approach and Caregiver Consent for Deceased Organ Donation in a Canadian Province (2015-2021).Clinical transplantation · 2024Observational
- Perspective on donor-derived infections in Italy.Transplant infectious disease : an official journal of the Transplantation Society · 2024Review
- HOPE springs eternal: lack of HIV superinfection in HIV Organ Policy Equity Act kidney transplants.The Journal of clinical investigation · 2024Article
- Evolution of heart transplant donor characteristics in the 21World journal of transplantation · 2024Review
- Overcoming barriers and stigma: new frontiers in solid organ transplantation for people with HIV.Clinical microbiology reviews · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors at 13 institutions in 1 country.
Funding
Abstract
Liver transplantation (LT) from donors-with-HIV to recipients-with-HIV (HIV D+/R+) is permitted under the HOPE Act. There are only three international single-case reports of HIV D+/R+ LT, each with limited follow-up. We performed a prospective multicenter pilot study comparing HIV D+/R+ to donors-without-HIV to recipients-with-HIV (HIV D-/R+) LT. We quantified patient survival, graft survival, rejection, serious adverse events (SAEs), human immunodeficiency virus (HIV) breakthrough, infections, and malignancies, using Cox and negative binomial regression with inverse probability of treatment weighting. Between March 2016-July 2019, there were 45 LTs (8 simultaneous liver-kidney) at 9 centers: 24 HIV D+/R+, 21 HIV D-/R+ (10 D- were false-positive). The median follow-up time was 23 months. Median recipient CD4 was 287 cells/µL with 100% on antiretroviral therapy; 56% were hepatitis C virus (HCV)-seropositive, 13% HCV-viremic. Weighted 1-year survival was 83.3% versus 100.0% in D+ versus D- groups (p = .04). There were no differences in one-year graft survival (96.0% vs. 100.0%), rejection (10.8% vs. 18.2%), HIV breakthrough (8% vs. 10%), or SAEs (all p > .05). HIV D+/R+ had more opportunistic infections, infectious hospitalizations, and cancer. In this multicenter pilot study of HIV D+/R+ LT, patient and graft survival were better than historical cohorts, however, a potential increase in infections and cancer merits further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.